Esperion Therapeutics,Inc. (NASDAQ:ESPR) Files An 8-K Other EventsItem 8.01 Other Events
On March27, 2018, Esperion Therapeutics,Inc. issued a press release titled, “Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor in Patients with Hypercholesterolemia” (the “Press Release”). A copy of the Press Release is filed herewith as Exhibit99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
|
ExhibitNo.
|
Description
|
|
99.1
|
Press Release dated March27, 2018.
|
***
Esperion Therapeutics, Inc. ExhibitEX-99.1 2 a18-9065_1ex99d1.htm EX-99.1 Exhibit 99.1 Media Contact: Elliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Audrey Gross W2O Group 212.301.7214 agross@w2ogroup.com Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor in Patients with Hypercholesterolemia Study Met Primary Endpoint with 30% Additional LDL-C Lowering hsCRP Reduction of 34% Observed to be Safe and Well-Tolerated in This Study Conference Call and Webcast on Tuesday,…To view the full exhibit click here
About Esperion Therapeutics,Inc. (NASDAQ:ESPR)
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company’s lead product candidate is ETC-1002, or bempedoic acid. The Company is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors.